Picture loading failed.

Anti-CD38 therapeutic antibody (Pre-made Isatuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-279-1mg 1mg 3090
GMP-Bios-ab-279-10mg 10mg 21890
GMP-Bios-ab-279-100mg 100mg 148000
GMP-Bios-ab-279-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD38 therapeutic antibody (Pre-made Isatuximab biosimilar,Whole mAb)
INN Name Isatuximab
TargetCD38
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure4cmh:BC
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesImmunoGen;Huntsman Cancer Institute;Roche;Sanofi
Conditions ApprovedMultiple myeloma
Conditions ActiveAcute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer
Conditions DiscontinuedNon-small cell lung cancer;Prostrate cancer;T-cell lymphoma
Development Techna